Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M218,064Revenue $M58,831Net Margin (%)15.6Z-Score3.2
Enterprise Value $M231,679EPS $3.7Operating Margin %18.5F-Score6
P/E(ttm))22.6Cash Flow Per Share $5.5Pre-tax Margin (%)18.3Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %7.0Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %10.0Current Ratio1.1Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %0.9ROA % (ttm)7.3Higher Current Ratio y-yY
Dividend Yield %3.1Insider Buy (3m)0ROE % (ttm)12.3Less Shares Outstanding y-yN
Payout Ratio %69.0Shares Outstanding M2,447ROI % (ttm)10.2Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 89.5210%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 89.5210%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 89.5215%Reduce -66.76%267,321
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 89.5223%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 89.5223%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 89.5223%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 89.5232%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 89.5232%Reduce -85.39%726,200
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 89.5245%Add 2.65%48,438,459
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 89.5253%Add 3.23%47,187,759
NVSMario Gabelli 2012-03-31 Reduce$53.31 - $58.33
($52.37)
$ 89.5271%Reduce -37.42%11,740
NVSMichael Price 2012-03-31 Sold Out -1.3%$53.31 - $58.33
($52.37)
$ 89.5271%Sold Out0
NVSJohn Hussman 2012-03-31 Reduce-0.14%$53.31 - $58.33
($52.37)
$ 89.5271%Reduce -22.44%515,000
NVSMichael Price 2011-06-30 Buy 1.29%$54.23 - $64.52
($59.61)
$ 89.5250%New holding, 144969 sh.144,969
NVSVanguard Health Care Fund 2011-06-30 Add0.45%$54.23 - $64.52
($59.61)
$ 89.5250%Add 30.01%4,869,880
NVSMario Gabelli 2011-06-30 Add$54.23 - $64.52
($59.61)
$ 89.5250%Add 65.83%20,215
NVSMario Gabelli 2011-03-31 Reduce$52.75 - $59.24
($56.19)
$ 89.5259%Reduce -95.51%12,190
NVSVanguard Health Care Fund 2010-12-31 Reduce-0.42%$53.41 - $59.77
($57.3)
$ 89.5256%Reduce -21.07%4,869,880
NVSJohn Hussman 2010-12-31 Reduce-0.34%$53.41 - $59.77
($57.3)
$ 89.5256%Reduce -35.87%643,500
NVSMario Gabelli 2010-09-30 Buy 0.07%$47.85 - $58.09
($51.82)
$ 89.5273%New holding, 272290 sh.272,290
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Lee Ainslie 2014-03-31351,5800.010.42+31.52%
NVS John Hussman 2014-03-31221,2000.011.4
NVS Jean-Marie Eveillard 2014-03-3113,06000
NVS Dodge & Cox 2014-03-3146,441,1691.94-0.1%
NVS Tweedy Browne 2014-03-31291,5000.010.57-0.29%
NVS Mario Gabelli 2014-03-3110,74000-0.92%
NVS PRIMECAP Management 2014-03-3124,014,5860.982.3-10.13%
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Sarah Ketterer’s Causeway International Value’s Top Five Holdings Jun 05 2014 
      Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks May 29 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      These Three Pharmaceutical Companies Shake The Market With Their Deal Apr 27 2014 
      The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
      PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
      Diversification, Growth and Undervalued Stocks – Utilizing GuruFocus’ Global Gurus Apr 09 2014 
      Is Grifols Being Overlooked? Mar 19 2014 
      Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks Mar 12 2014 
      Top Three Holdings of a Top Investment Advisory Firm Mar 06 2014 

      More From Our Partners
      Novartis' Phase III Results on Secukinumab Published - Analyst Blog Jul 10 2014 - ZACKS

      More From Other Websites
      Look Internationally For Higher Dividend Yields Jul 10 2014
      Novartis' Phase III Results on Secukinumab Published Jul 10 2014
      Pharma's Poor Reputation Doesn't Help In The Fight Against Superbugs Jul 10 2014
      Novartis announces NEJM publication of two phase III studies demonstrating high efficacy of... Jul 09 2014
      Incyte Earns Milestone Payment on Japanese Approval of Jakavi Jul 09 2014
      Hanmi-Novartis, co-marketing 'Galvus', treatment for diabetes Jul 09 2014
      Novartis releases 2013 Corporate Responsibility Performance Report using best-in-class reporting... Jul 09 2014
      Punishing Walgreen For Leaving The U.S. Might Be More Complicated Than Robert Reich Thinks Jul 08 2014
      Former Novartis Exec: I was Fired for Complaining About a Possible Kickback Jul 08 2014
      Novartis' CTL109 Gets Breakthrough Therapy Designation from the FDA Jul 08 2014
      How Flu Tried To Steal The World Cup's Thunder Jul 08 2014
      Novartis Issues Research Guidelines After Japan Study Scandal Jul 08 2014
      Novartis reinforces its leadership in research with new global guidelines for Investigator Initiated... Jul 08 2014
      2:04 am Novartis reinforces its leadership in research with new global guidelines for Investigator... Jul 08 2014
      [$$] Novartis Wins 'Breakthrough' Status for New Leukemia Treatment Jul 08 2014
      Time To Take Profits In Novartis And AstraZeneca? Jul 07 2014
      Novartis cell treatment named "Breakthrough Therapy" in US Jul 07 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide